Myomo (MYO) Cash from Operations Growth (3y) (2019 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 20.35% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -48.14% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 0.50% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 50.11% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -14.75% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 15.83% |
| 10 | Myomo | 44.63 Mn | 26.23 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 13.22% |
| Jun 30, 2025 | -49.60% |
| Mar 31, 2025 | -4.85% |
| Dec 31, 2024 | 56.60% |
| Sep 30, 2024 | 12.35% |
| Jun 30, 2024 | 17.30% |
| Mar 31, 2024 | -15.39% |
| Dec 31, 2023 | -27.64% |
| Sep 30, 2023 | 1.60% |
| Jun 30, 2023 | 57.25% |
| Mar 31, 2023 | 9.43% |
| Dec 31, 2022 | 2.32% |
| Sep 30, 2022 | -6.91% |
| Jun 30, 2022 | -5.00% |
| Mar 31, 2022 | 9.37% |
| Dec 31, 2021 | 10.06% |
| Sep 30, 2021 | 3.67% |
| Jun 30, 2021 | -13.04% |
| Mar 31, 2021 | 2.30% |
| Dec 31, 2020 | 9.77% |
| Sep 30, 2020 | 1.16% |
| Jun 30, 2020 | -32.11% |
| Mar 31, 2020 | -28.15% |
| Dec 31, 2019 | -43.02% |
| Sep 30, 2019 | -20.34% |